Gene · 4300
Papers2,395
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,395
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. | EMBO Mol Med | 2023 | 36453131 | PubTator, text mining | PubMed |
| Repurposing immunosuppressants for antileukemia therapy. | EMBO Mol Med | 2023 | 36453114 | PubTator, text mining | PubMed |
| The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes. | Int J Lab Hematol | 2023 | 36358022 | PubTator, text mining | PubMed |
| miR-148a-3p and DDX6 functional link promotes survival of myeloid leukemia cells. | Blood Adv | 2023 | 36322827 | PubTator, text mining | PubMed |
| A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. | Cancer Discov | 2023 | 36264143 | PubTator, text mining | PubMed |
| Clinical features and outcomes of fusion gene defined adult Ph-negative B-cell precursor acute lymphoblastic leukemia patients: A single institutional report. | Biomol Biomed | 2023 | 36124444 | PubTator, text mining | PubMed |
| Knock-out of 5-lipoxygenase in overexpressing tumor cells-consequences on gene expression and cellular function. | Cancer Gene Ther | 2023 | 36114329 | PubTator, text mining | PubMed |
| Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. | Haematologica | 2023 | 36073516 | PubTator, text mining | PubMed |
| Crosstalk between β-catenin and WT1 signaling activity in acute myeloid leukemia. | Haematologica | 2023 | 35443562 | PubTator, text mining | PubMed |
| Chemical Biology Approaches to Identify and Profile Interactors of Chromatin Modifications. | ACS Chem Biol | 2023 | 35238546 | PubTator, text mining | PubMed |
| Regulatory roles of an atypical ubiquitin ligase UBE2O in orphans of multiprotein complexes for degradation. | Turk J Biol | 2022 | 37533513 | PubTator, text mining | PubMed |
| Manifold Interpolating Optimal-Transport Flows for Trajectory Inference. | Adv Neural Inf Process Syst | 2022 | 37397786 | PubTator, text mining | PubMed |
| Association of iKIR-mismatch model and donor aKIRs with better outcome in haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. | Front Immunol | 2022 | 36761162 | PubTator, text mining | PubMed |
| Dysregulated Expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in Patients with Acute Myeloid Leukemia and Association with Graft versus Host Disease after Hematopoietic Stem Cell Transplantation. | South Asian J Cancer | 2022 | 36756106 | PubTator, text mining | PubMed |
| Candidate targets of copy number deletion events across 17 cancer types. | Front Genet | 2022 | 36726722 | PubTator, text mining | PubMed |
| [Dynamic assessment of WT1 for predicting the relapse of acute myeloid leukemia patients with MLL rearrangements after hematopoietic stem cell transplantation]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | 36709175 | PubTator, text mining | PubMed |
| Inference of gene-environment interaction from heterogeneous case-parent trios. | Front Genet | 2022 | 36685810 | PubTator, text mining | PubMed |
| Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies. | Biomolecules | 2022 | 36671446 | PubTator, text mining | PubMed |
| Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance. | Cancer Drug Resist | 2022 | 36627892 | PubTator, text mining | PubMed |
| Optical Genome Mapping for Comprehensive Assessment of Chromosomal Aberrations and Discovery of New Fusion Genes in Pediatric B-Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2022 | 36612032 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4300/papers?page=17